Compared to mainstream drug launches, it’s usually a much smaller team with fewer resources that are tasked with bringing a new orphan drug to market. And the market itself is smaller too – fewer specialists to talk to, fewer physicians to educate, and fewer patients to engage with.
But smaller doesn’t mean less important.
Every activity is so much more visible, which makes the pressure to get it right first time even more intense than usual. And the higher price tag associated with rare disease treatments means that the commercial risks and the potential benefits are far from small either. Launching an orphan drug is clearly not for the faint-hearted.
This report will enable you to:
- Compare the experiences of 8 pharma companies who have successfully launched at least one orphan drug, including Celgene, GlaxoSmithKline, Roche, Boehringer Ingelheim and Pfizer.
- Understand which factors should be considered when setting orphan drug prices and find out about the specific pricing strategies adopted for each case study drug.
- Assess the stakeholder engagement strategies needed to address the barriers to success that exist for rare disease therapies.
